Patents by Inventor Kunjuraman SUJATHAN

Kunjuraman SUJATHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Screening kit for detection of grades of cervical cancer and process for the preparation thereof
    Patent number: 11313860
    Abstract: The capabilities of using gold nanoparticle as surface-enhanced Raman scattering (SERS) substrate to obtain cervical smear harvested cells biochemical information for non-invasive cervical precancerous detection were presented in this patent document. A SERS reagent and a platform has been developed and optimized for the generation of a differential spectral fingerprinting for cervical cancer detection. SERS measurements were performed on three group's cervical exfoliated cell samples: one group from patients (n=36) with pathologically confirmed cervical cancer and another group with high-grade squamous intraepithelial lesion (HSIL) (n=41) and the last group from healthy volunteers (control subjects, n=47).
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: April 26, 2022
    Assignee: Council of Scientific & Industrial Research
    Inventors: Kaustabh Kumar Maiti, Varsha Karunakaran, Kunjuraman Sujathan
  • SCREENING KIT FOR DETECTION OF GRADES OF CERVICAL CANCER AND PROCESS FOR THE PREPARATION THEREOF
    Publication number: 20220065860
    Abstract: The capabilities of using gold nanoparticle as surface-enhanced Raman scattering (SERS) substrate to obtain cervical smear harvested cells biochemical information for non-invasive cervical precancerous detection were presented in this patent document. A SERS reagent and a platform has been developed and optimized for the generation of a differential spectral fingerprinting for cervical cancer detection. SERS measurements were performed on three group's cervical exfoliated cell samples: one group from patients (n=36) with pathologically confirmed cervical cancer and another group with high-grade squamous intraepithelial lesion (HSIL) (n=41) and the last group from healthy volunteers (control subjects, n=47).
    Type: Application
    Filed: July 24, 2019
    Publication date: March 3, 2022
    Inventors: Kaustabh Kumar MAITI, Varsha KARUNAKARAN, Kunjuraman SUJATHAN